FDA approves first cell-based gene therapy for rare, devastating skin disorder – but it comes with a huge price tag

Estimated read time 1 min read

(NaturalNews) The FDA approved Zevaskyn, the first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare and painful genetic dis…

You May Also Like

More From Author